Bedoradrine sulfate

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529534

CAS#: 194785-31-4 (Bedoradrine sulfate)

Description: Bedoradrine sulfate is a β2-adrenoceptor agonist potentially for the treatment of asthma.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-10-25. Prices are subject to change without notice.

Bedoradrine sulfate is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 529534
Name: Bedoradrine sulfate
CAS#: 194785-31-4 (Bedoradrine sulfate)
Chemical Formula: C24H34N2O9S
Exact Mass:
Molecular Weight: 526.601
Elemental Analysis: C, 54.74; H, 6.51; N, 5.32; O, 27.34; S, 6.09

Related CAS #: 194785-19-8 (Bedoradrine free base)  

Synonym: MN-221; KUR-1246; MN221; KUR1246; MN 221; KUR 1246

IUPAC/Chemical Name: 2-(((S)-7-(((R)-2-hydroxy-2-(4-hydroxy-3-(2-hydroxyethyl)phenyl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-2-yl)oxy)-N,N-dimethylacetamide sulfate


InChi Code: InChI=1S/C24H32N2O5.H2O4S/c1-26(2)24(30)15-31-21-7-4-16-3-6-20(12-19(16)13-21)25-14-23(29)17-5-8-22(28)18(11-17)9-10-27;1-5(2,3)4/h4-5,7-8,11,13,20,23,25,27-29H,3,6,9-10,12,14-15H2,1-2H3;(H2,1,2,3,4)/t20-,23-;/m0./s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Matsuda K, Makhay M, Johnson K, Iwaki Y. Evaluation of bedoradrine sulfate (MN-221), a novel, highly selective beta2-adrenergic receptor agonist for the treatment of asthma via intravenous infusion. J Asthma. 2012 Dec;49(10):1071-8. doi: 10.3109/02770903.2012.729631. PubMed PMID: 23094708.

2: House SL, Matsuda K, O'Brien G, Makhay M, Iwaki Y, Ferguson I, Lovato LM, Lewis LM. Efficacy of a new intravenous β2-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma. Respir Med. 2015 Oct;109(10):1268-73. doi: 10.1016/j.rmed.2015.08.003. PubMed PMID: 26324315.

3: Antoniu S. Bedoradrine for treating asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2014 Aug;23(8):1149-56. doi: 10.1517/13543784.2014.928284. Review. PubMed PMID: 24938936.

4: Inoue Y, Yoshizato T, Kawarabayashi T. Investigation of beta(2)-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant. J Obstet Gynaecol Res. 2009 Jun;35(3):405-13. doi: 10.1111/j.1447-0756.2008.01001.x. PubMed PMID: 19527375.

5: Travers AH, Milan SJ, Jones AP, Camargo CA Jr, Rowe BH. Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma. Cochrane Database Syst Rev. 2012 Dec 12;12:CD010179. doi: 10.1002/14651858.CD010179. Review. PubMed PMID: 23235685.

6: Gross N. The COPD pipeline XX. COPD. 2013 Feb;10(1):104-6. doi: 10.3109/15412555.2013.766103. PubMed PMID: 23413896.

7: Furihata Y, Kobayashi M, Kojima M, Kobayashi K, Kawarabayashi T, Yamamoto T. Effects of KUR-1246, a selective uterine relaxant, on transplacental passage and transmigration to milk. J Obstet Gynaecol Res. 2006 Feb;32(1):4-9. PubMed PMID: 16445519.

8: Furihata Y, Motokawa Y, Murata S, Kiguchi S, Kobayashi M, Murakami M, Kojima M, Yamamoto T. Cardiovascular effects of KUR-1246, a new tetrahydronaphthalen derivative beta2-adrenoceptor agonist and a selective uterine relaxant. Arzneimittelforschung. 2006;56(1):18-24. PubMed PMID: 16478001.

9: Murata S, Matsuda T, Kiguchi S, Kobayashi M, Cho K, Okuyama K. Effects of long term administration of KUR-1246, a selective beta(2)-adrenoceptor agonist, on pregnant sheep and their fetuses. BJOG. 2005 Jan;112(1):69-74. PubMed PMID: 15663400.

10: Kiguchi S, Matsuda T, Cho K, Okuyama K, Akahane M, Fujimoto S. KUR-1246, a novel beta(2)-adrenoceptor agonist, as a tocolytic agent. Obstet Gynecol. 2002 Sep;100(3):487-94. PubMed PMID: 12220768.

11: Sakakibara T, Inoue Y, Uzue S, Tsukamoto T, Kobayashi M, Kojima M, Akahane M, Kitamura K, Kawarabayashi T. Diversity of inhibitory responses to beta2-stimulants shown by term-pregnant human myometria in vitro is partly due to differences in receptor density. Am J Obstet Gynecol. 2002 May;186(5):997-1004. PubMed PMID: 12015527.

12: Yanagi T, Kikuchi K, Takeuchi H, Ishikawa T, Nishimura T, Yamamoto I. The practical synthesis of a uterine relaxant, bis(2-[[(2S)-2-([(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)-phenyl]ethyl]amin o)-1,2,3,4-tetrahydronaphthalen-7-yl]oxy]-N,N-dimethylacetamide) sulfate (KUR-1246). Chem Pharm Bull (Tokyo). 2001 Aug;49(8):1018-23. PubMed PMID: 11515570.

13: Kobayashi M, Takeda K, Murata S, Kojima M, Akahane M, Inoue Y, Kitamura K, Kawarabayashi T. Pharmacological characterization of KUR-1246, a selective uterine relaxant. J Pharmacol Exp Ther. 2001 May;297(2):666-71. PubMed PMID: 11303056.